Kainos Medicine카이노스메드
284620 · KOSDAQ · ₩284620 · 카이노스메드
₩1,087 ₩0 (0.00%)End-of-day · Oct 27, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩1.2B | ₩590M | ₩267M | ₩130M | ₩1.7B |
| Cost of sales | ₩972M | ₩169M | ₩62M | ₩39M | ₩2.2M |
| Gross profit | ₩200M | ₩422M | ₩205M | ₩91M | ₩1.7B |
| Operating income | −₩6.4B | −₩12B | −₩17B | −₩16B | −₩11B |
| Net income | −₩7.8B | −₩12B | −₩15B | −₩16B | −₩16B |
| Net income to shareholders | −₩7.8B | −₩12B | −₩15B | −₩16B | ₩16B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩6.6B | ₩11B | ₩21B | ₩39B | ₩42B |
| Current assets | ₩4.4B | ₩4.6B | ₩17B | ₩31B | ₩37B |
| Cash and equivalents | ₩2.9B | ₩3.8B | ₩16B | ₩25B | ₩23B |
| Total liabilities | ₩2B | ₩4.9B | ₩5.2B | ₩9.1B | ₩27B |
| Current liabilities | ₩2B | ₩4.7B | ₩5.1B | ₩8.7B | ₩26B |
| Borrowings | — | ₩0 | ₩0 | ₩3B | ₩14B |
| Total equity | ₩4.6B | ₩5.9B | ₩16B | ₩30B | ₩15B |
| Shareholders' equity | ₩1.1B | ₩1.8B | ₩12B | ₩26B | ₩12B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | −₩5.9B | −₩9.7B | −₩14B | −₩11B | −₩9.2B |
| Capital spending | ₩5.5M | ₩80,000 | ₩4B | ₩1.8B | ₩1.9B |
| Free cash flow | −₩5.9B | −₩9.7B | −₩18B | −₩13B | −₩11B |
Consolidated where available. Amounts in won.
Also known as: Kainos Medicine / 카이노스메드 / 284620 / KRX:284620
Source: KRX statistical information